BC Innovations | Jan 3, 2019
Distillery Therapeutics


INDICATION: Liver cancer Cell culture and mouse studies suggest inhibiting the HMG-CoA reductase/SQLE/LSS pathway could help treat p53-deficient liver cancer. In human liver adenocarcinoma cell lines, levels of two metabolic intermediates biosynthesized by the pathway...
BC Innovations | Aug 13, 2015
Distillery Therapeutics

Therapeutics: Crystallin α A (CRYAA; HSPB4); lanosterol synthase (LSS)

Ophthalmic disease INDICATION: Cataract In vitro and dog studies suggest the steroid precursor lanosterol could help treat cataracts caused by aggregation of CRYAA and other crystallin proteins in lens fibers. In human lens progenitor cells...
Items per page:
1 - 2 of 2